Pharmacological therapies for the prevention of fractures in men. (PubMed, Cochrane Database Syst Rev) - Sep 16, 2026 - "We are very uncertain about the effects of bisphosphonates compared to placebo on the incidence of hip fractures, symptomatic vertebral fractures, or other (non-hip non-vertebral) fractures in men at up to two years of use. Bisphosphonates probably do not increase the risk of adverse events or serious adverse events, and we are very uncertain if they result in more withdrawals due to adverse events. We downgraded the certainty of evidence for indirectness, imprecision (low event rate), and serious risk of bias in selection of the reported result, as it was unclear if all studies fully reported every fracture. We found similar results for PTH or PTHrP analogues, denosumab, or romosozumab versus placebo. Larger, longer placebo-controlled studies are needed to determine whether pharmacological therapies are beneficial for reducing fractures in men."
Clinical • Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology
|
|
Cyrill Suter; Lars Christian Braten; Rachelle Buchbinder; Renea V Johnston; Sami A Hartzell; Teppo Järvinen
|